Please login to the form below

cancer

This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Like Kadcyla, DS-8201 combines the HER2-targeting of trastuzumab with a cell-killing chemotherapy component designed to improve its ability to kill breast cancer cells. ... ovarian and breast cancer which collectively brought in more than $3bn in

Latest news

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Pancreatic cancer is currently the seventh leading cause of cancer death worldwide, and number three in the US, having overtaken breast cancer a few years ago. ... Earlier-stage trials are ongoing in other advanced solid tumours including melanoma,
Litigation concerns threaten to overshadow solid quarter at J&J

Growth for immunology therapy Stelara (ustekinumab) and blood cancer drugs Imbruvica (ibrutinib) and Darzalex (daratumumab) – plus Stelara follow-up Tremfya (guselkumab) – outweighed the effect of generic competition to older prostate cancer
Roche reports continued growth in Q3, despite biosimilar competition

According to the Swiss pharma, the key drivers of this growth were mutliple sclerosis medicine Ocrevus, new haemophilia treatment Hemlibra and its cancer medicines – Tecentriq, Perjeta and Avastin. ... The company also reported growth in its
Increased discount leads NICE to reverse positon on Clovis cancer drug

Ovarian cancer drug Rubraca now recommended for use within the Cancer Drugs Fund. ... Rubraca was also the first PARP inhibitor authorised to treat ovarian cancer in Europe.
Gilead builds case for Xeljanz rival filgotinib as it preps US filing

its HIV franchise, to include new areas like cancer, liver disease and immunology.

More from news
Approximately 639 fully matching, plus 2,907 partially matching documents found.

Latest Intelligence

A snapshot of Crescendo Biologics

What is the central focus of Crescendo’s research? The company is focused on T-cell enhancement to develop new ways to treat difficult cancer types. ... success – or to make advances in those cancers that are still difficult to treat in this way.
Leading AstraZeneca’s return to growth in Europe

the only PARP inhibitor with positive phase 3 results in four different cancer types (ovarian, breast, pancreatic and prostate). ... That’s a measure of its heightened ambitions in oncology, especially as Roche is dominant in the HER2 breast cancer
The evolution of marketing – the Amgen way

There is tremendous opportunity – and a massive need – to bend the curve for serious illnesses, such as cancer, cardiovascular disease and osteoporosis, which affect tens of millions of people worldwide.
Changing direction: adapting to a rapidly-evolving environment

AI is making it easier to identify people at risk of serious diseases like dementia, AKI and major cancers.
European biotech: a new generation of leaders emerges

In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline.

More from intelligence
Approximately 8 fully matching, plus 283 partially matching documents found.

Latest appointments

Lucid Group announces new hires at its creative and digital agency Bluedog

Finally, Victoria William joins Bluedog as a senior account executive. William has two years’ experience working at an independent creative healthcare agency, and also has a MSc in cancer cell biology.
F-star hires ex-BMS immuno-oncology leader

pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical
New hires at Ferring, Flexion and Immunocore

It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;
New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics

He started his career with Eurand in Italy, and since 2011 he has worked for Helsinn Healthcare, a cancer care company.

More from appointments
Approximately 5 fully matching, plus 203 partially matching documents found.

Latest from PMHub

Mednet Group’s growth spurt

in cancer biology and she has experience working as a research technician in the field of malignant haematology. .
Qualitative segmentation validation study with backroom brainstorm exercises

Our client had an oncology product in development for the treatment of prostate cancer.
Empowered patients: shaking the foundations of healthcare

Those practicing in a community care setting often lack knowledge of precise treatments, as shown in our interview with breast cancer survivor Laura Holmes-Haddad (on p.10). ... As a result, the ‘zip code lottery’ and patients’ financial
Bluedog is bursting with new creative and digital talent

Finally, Victoria William joins Bluedog as a senior account executive. Victoria has an MSc in cancer cell biology and two years’ experience working at an independent creative healthcare agency.
Precision paediatrics: Treating patients with CAR-T

The therapy works by modifying T-cells to weaponise them against cancer cells. ... SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells.